The Value Of Real-World Evidence In Canadian Drug Commercialization

Real-world evidence (RWE) is reshaping how Canadian biopharma and biosimilar companies build their market access and commercialization strategies. As health technology agencies and payers place greater weight on value and outcomes, clinical trial data alone no longer tells the full story. RWE fills that gap by capturing drug effectiveness across broader, more diverse patient populations in routine clinical practice settings.

Data sources range from hospital administrative records and pharmacy claims to patient-reported outcomes, wearables, and provincial health databases. Each source layer adds context that RCTs simply cannot provide given their controlled design and narrowly defined patient criteria. Across the product lifecycle, from pre-launch disease epidemiology and budget impact modeling through post-authorization adherence monitoring and loss-of-exclusivity planning, RWE informs decisions at every stage. Building a proactive evidence generation strategy early ensures manufacturers are positioned to respond to payer questions with credible, locally relevant data.

Check out the full article for a breakdown of RWE applications at each lifecycle stage and the data sources that support them.